Shots: The designation is based on the ongoing P-III DIALIZE-Outcomes trial to evaluate the effect of Lokelma on arrhythmia-related CV outcomes in patients with chronic hemodialysis with recurrent HK at […]readmore
Tags : Lokelma
Shots: The EMA’s CHMP has adopted a positive opinion on a dosing and administration label update for AstraZeneca’s Lokelma to include patients with hyperkalemia on stable hemodialysis The recommendation is […]readmore
Shots: The MHLW’s approval is based on stand-alone studies in Japan and global clinical programs and is supported by DIALIZE study that demonstrated the efficacy on Lokelma in treating hyperkalemia […]readmore
Regulatory
AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients
Shots: The approval is based on four trials assessing Lokelma vs PBO in patients with hyperkalemia treated for up to 12 months The study resulted in a median time of […]readmore
Shots: The P-IIIb DIALIZE study results involve assessing of Lokelma vs PBO in n 196 patients on hemodialysis with hyperkalemia in ESRD The P-IIIb DIALIZE study resulted in maintaining normal […]readmore
Shots: The approval is based on five studies assessing Lokelma vs PBO in patients with hyperkalaemia The study resulted in onset of action was at 1.0 hour and the median […]readmore